Stock Market Reviews

OLMA (Olema Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on OLMA (Olema Pharmaceuticals, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Olema Oncology to Participate in Upcoming Investor Conferences
  SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Date and Time: November 10, 2025 at 10:30 a.m. ET Format: Fireside C
  Nov 3, 2025 - $OLMA
• Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
  SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) taking place December 9-12, 2025 in San Antonio, TX. The trial is evalu
  Oct 30, 2025 - $OLMA
• Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports
  US stocks look set to open higher in Monday's trading session ahead of a raft of earnings coming out
  Oct 20, 2025 - $OLMA
• Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector
  Olema Pharmaceuticals (OLMA) shares fell 14% in Monday trading even after encouraging results for it
  Oct 20, 2025 - $OLMA
• Investors Look Ahead to Key Earnings Reports as US Futures Rise Monday Pre-Bell
  US stock futures were tracking higher in Monday's premarket session as investors look to earnings re
  Oct 20, 2025 - $OLMA
• Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
  Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumorsCombination continues to demonstrate favorable tolerability and a safety profile consistent with the known pr
  Oct 18, 2025 - $OLMA
• Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential
  Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target. The firm views Olema as the top biotech for selective estrogen receptor degrader/SERD breast cancer drugs. Guggenheim cited its palazestrant as the most promising […]
  Oct 16, 2025 - $OLMA
• Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)
  Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 […]
  Sep 30, 2025 - $OLMA
• OLMA Stock Soars 47% in September So Far on Second PFE Deal
  Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
  Sep 12, 2025 - $OLMA
• Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals
  Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On September 2, Pfizer Inc. (NYSE:PFE) announced a new trial collaboration with Olema Pharmaceuticals for metastatic breast cancer. The study will test the safety and effectiveness of combining Olema’s drug Palazestrant with Pfizer’s investigational drug Atirmociclib. Both drugs target estrogen […]
  Sep 7, 2025 - $OLMA